Generic and biosimilar drugs are much lower priced than their on-label counterparts, but biosimilars in particular are not prescribed as widely as they could be. AtlanticLIVE convened experts to discuss the obstacles and the implications. Jeanne’s panelists included Vermont Senator Peter Welch, Murray Aitken of the IQVIA Institute for Human Data Science, and Christine Baeder, President of Apotex USA.
Photo credit: Tony Powell
